An engineered adipose formulation decreases hepatic inflammation and fibrosis in a rodent model of metabolic dysfunction-associated steatotic liver disease
AF has the potential to treat MASH. Future studies focused on the optimization of AF composition, optimal dose and treatment regimen are warranted.
Authors
- Sarah E. Tom (ORCID: https://orcid.org/0000-0003-0094-5138)
- Liqing Yu (ORCID: https://orcid.org/0000-0002-5186-9182)
- Alla Danilkovitch (ORCID: https://orcid.org/0000-0001-5413-6737)
- Yinyan Ma (ORCID: https://orcid.org/0009-0004-6682-0228)
- Youngshim Choi (ORCID: https://orcid.org/0000-0002-0735-6072)
Institutions
- University of Maryland, Baltimore (US)
- Incyte (United States) (US)
Publication Details
- Journal
- Frontiers in Bioengineering and Biotechnology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.3389/fbioe.2025.1579062
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Maryland Stem Cell Research Fund
- National Institute of Diabetes and Digestive and Kidney Diseases